Jodie Morrison, Q32 Bio CEO
November 16, 2023 08:44 AM ESTUpdated 03:01 PM
Startups
Deals

Q32 Bio to take Ho­mol­o­gy Med­i­cines’ Nas­daq spot to fund PhII tri­als in au­toim­mune, in­flam­ma­to­ry con­di­tions

Kyle LaHucik

Senior Reporter

The re­verse merg­ers are flow­ing. Q32 Bio will take Ho­mol­o­gy Med­i­cines’ place on the Nas­daq, the com­pa­nies said Thurs­day …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Leg­end names a pres­i­dent of Carvyk­ti; No­vo Nordisk's top North Amer­i­ca ex­ec is step­ping down

Athi­ra gives up on lead Alzheimer’s drug, switch­es tack to ALS

Nkar­ta drops an­oth­er can­cer pro­gram as it leans in­to au­toim­mune dis­ease

Se­nior As­traZeneca ex­ec de­tained in Chi­na amid wider in­ves­ti­ga­tion

Soft RSV sales re­veal a vac­cine mar­ket fail­ing to catch post-Covid mo­men­tum

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times